[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100452900":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":39,"locations":44,"responsibleParty":60,"collaborators":62,"id":65,"slug":10,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":72,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":10,"studyType":79,"phases":10,"briefSummary":80,"conditions":81,"keywords":86,"overallStatus":47,"whyStopped":10,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"University Hospital, Basel, Switzerland","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"MS patient group",null,"Recruitment of 200 MS patients at the MS Clinic of the Department of Neurology (Neurologische Klinik und Poliklinik), University Hospital Basel (Universitätsspital Basel)",[13,14],"Diagnostic Test: MRI","Other: blood sampling",{"label":16,"type":10,"description":17,"interventionNames":18},"control group (HC)","Recruitment of 100 healthy controls (HC) by public announcements (i.e. advertisement\u002Fflyer) on the University Hospital's and the University's notice board.",[13,19,14],"Other: Neurocognitive examination for healthy subjects",[21,26,30],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":10},"DIAGNOSTIC_TEST","MRI","Each enrolled subject will undergo a MRI at baseline and a second MRI at 2 years (+\u002F- 3 months) follow-up.",[9,16],{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":10},"Neurocognitive examination for healthy subjects","Neurocognitive examination for healthy subjects will be performed at both baseline and follow-up",[16],{"type":6,"name":31,"description":32,"armGroupLabels":33,"otherNames":10},"blood sampling","Each enrolled subject will undergo a blood sampling (10 ml) at baseline",[9,16],[35],{"name":36,"affiliation":37,"role":38},"Cristina Granziera, Prof. Dr. med.","Department of Neurology, University Hospital Basel","PRINCIPAL_INVESTIGATOR",[40],{"name":36,"role":41,"phone":42,"phoneExt":10,"email":43},"CONTACT","+41 61-32 85 665","cristina.granziera@usb.ch",[45],{"facility":46,"status":47,"city":48,"state":10,"zip":49,"country":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"University Hospital Basel, Department of Neurology","RECRUITING","Basel","4031","Switzerland",{"type":52,"coordinates":53},"Point",[54,55],7.57327,47.55839,{"lat":55,"lon":54},[58,59],{"name":36,"role":41,"phone":10,"phoneExt":10,"email":43},{"name":36,"role":38,"phone":10,"phoneExt":10,"email":10},{"type":61,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[63],{"name":64,"class":6},"Swiss National Science Foundation","100452900",false,"NCT05177523","Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis","INsIDER: Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis","INsIDER","Inclusion Criteria for patients:\n\n* Patients may be diagnosed with:\n\n  1. active RRMS (n=100): Relapsing-remitting course and \\> 1 clinical relapse and\u002For signs of MRI activity (\\> 1 Gd enhancing lesion) during the last year before study enrollment.\n  2. non-active PMS (n=100): Progressive course (PPMS or SPMS) and no clinical relapses and\u002For signs of MRI activity during the last year before study enrollment.\n* Age 18-80 years old\n* No other neurological or psychiatric disorder\n\nInclusion criteria for healthy controls:\n\n* Age 18-80 years old\n* No other neurological or psychiatric disorder\n\nExclusion Criteria for patients and healthy controls:\n\n* Pregnancy\n* Contraindication to MRI (eg, claustrophobia, metallic implants, pacemaker etc).\n* Inability to give consent",true,"ALL","18 Years","80 Years",{"count":77,"type":78},300,"ESTIMATED","OBSERVATIONAL","This project is to:\n\n1. Quantify differences in axonal integrity and organization in aMS versus naPMS patients.\n2. Quantify changes in axonal integrity and organization in aMS versus naPMS patients over a two-year period.\n3. Validate the combination of imaging parameters that best differentiate aMS versus naPMS patients using histopathology.",[82,83,84,85],"Multiple Sclerosis (MS)","Relapsing-remitting Multiple Sclerosis (RRMS)","Secondary-progressive Multiple Sclerosis (SPMS)","Primary Progressive Multiple Sclerosis (PPMS)",[87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102],"axonal damage","axonal demyelination","axonal degeneration","axonal loss","axonal disorganization","axonal repair","axonal remyelination","axonal reorganization","Advanced MRI (aMRI)","Neurite Orientation Dispersion and Density Imaging (NODDI)","Diffusion Kurtosis (DK)","Magnetization Transfer Imaging (MTI)","Multi-echo Susceptibility-Based imaging (SBI)","Myelin Water Imaging (MWI)","T1 relaxometry (quantitative T1, qT1)","machine learning technique","2024-12-13",{"date":105,"type":106},"2024-12-16","ACTUAL",{"date":108,"type":106},"2018-09-04",{"date":110,"type":78},"2028-12",{"name":5,"class":6},1]